Menlo Park, CA – According to filings with the U.S. Securities and Exchange Commission, Credence MedSystems is raising $40,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Jeff Shanley played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Credence MedSystems
Credence MedSystems is setting a new standard in drug delivery, helping our pharmaceutical customers differentiate their products through innovative delivery systems while preserving their trusted processes. Credence MedSystems has changed the paradigm for drug manufacturers commercializing an injectable drug in a differentiated delivery system. Credence MedSystems is an industry-recognized and award-winning innovator in injectable drug delivery devices for pharmaceutical and biotechnology manufacturers. The Companys broad family of drug delivery devices, which are protected by a robust intellectual property portfolio, addresses the evolving needs of the biopharmaceutical industry. Credences strategy of Innovation Without Change allows our biopharma customers to provide their end-users an enhanced user experience while minimizing implementation hurdles. Our delivery systems are built on the foundation of existing pre-filled syringes and components, enabling drug manufacturers to achieve marketable differentiation and cost-of-ownership advantages, while preserving their existing processes, sourcing preferences and the use of validated components. Credence is under the care of a seasoned team with extensive experience founding, leading and growing successful companies in the medical technology and drug delivery space.

To learn more about Credence MedSystems, visit http://www.credencemed.com/

Contact:
Jeff Shanley, Chief Executive Officer
844-263-3797

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved